Skip to main content
. 2015 Feb 19;18(7):pyu114. doi: 10.1093/ijnp/pyu114

Figure 1.

Figure 1.

Peripheral and central administered neuregulin 1 (NRG1) prevents PCP-induced hyperlocomotion in mice. (A & B) Post-treatment distance moved as percentage of habituation locomotion for varying doses of i.p. NRG1 (A, µg/kg) or i.c.v. NRG1 (B, ng/kg), administered in combination with PCP (3mg/kg) or vehicle (A, 0.9% NaCl; B, artificial cerebrospinal fluid + 0.9% NaCl). Data is presented as mean percentage difference to habituation locomotion + standard error of the mean (n = 8/group). (C & D) Mean distance moved within 5min windows pre- and post-treatment ± standard error of the mean (n = 8/group) after (C, i.p.) vehicle, NRG1 (25 μg/kg), PCP, or NRG1 + PCP (25 μg/kg + 3mg/kg); (D, i.c.v. + i.p.) vehicle, NRG1 (30ng/kg + 0.9% NaCl), PCP (artificial cerebrospinal fluid + 3mg/kg), or NRG1 + PCP (30ng/kg + 3mg/kg). *p < 0.05, **p < 0.01 vs PCP; #p < 0.01, ##p < 0.001, ###p < 0.0001 vs vehicle.